litlas
Log inCreate account

Frances A. Shepherd

Active 1983–2024

Also published as
FRANCES A. SHEPHERD
261
Papers
72,224
Citations
128
h-index
256
i10-index

Citations

Citations per year for Frances A. Shepherd1971: 4 citations1976: 1 citations1984: 1 citations1985: 5 citations1986: 5 citations1987: 16 citations1988: 11 citations1989: 17 citations1990: 13 citations1991: 28 citations1992: 23 citations1993: 23 citations1994: 30 citations1995: 19 citations1996: 20 citations1997: 36 citations1998: 37 citations1999: 44 citations2000: 47 citations2001: 60 citations2002: 99 citations2003: 122 citations2004: 161 citations2005: 276 citations2006: 400 citations2007: 437 citations2008: 449 citations2009: 570 citations2010: 610 citations2011: 622 citations2012: 540 citations2013: 624 citations2014: 451 citations2015: 476 citations2016: 435 citations2017: 560 citations2018: 609 citations2019: 1,824 citations2020: 2,036 citations2021: 2,021 citations2022: 1,570 citations2023: 1,145 citations2024: 1,728 citations2025: 868 citations2026: 18 citations1972–1975: no citations, so these years are not shown1977–1983: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,661 citing papers, 24.3% of this breakdownChina: 3,250 citing papers, 14% of this breakdownUnited Kingdom: 1,217 citing papers, 5.2% of this breakdownItaly: 1,140 citing papers, 4.9% of this breakdownCanada: 1,075 citing papers, 4.6% of this breakdownJapan: 1,052 citing papers, 4.5% of this breakdownFrance: 987 citing papers, 4.2% of this breakdownGermany: 970 citing papers, 4.2% of this breakdownSpain: 822 citing papers, 3.5% of this breakdownNetherlands: 608 citing papers, 2.6% of this breakdownSouth Korea: 575 citing papers, 2.5% of this breakdownAustralia: 528 citing papers, 2.3% of this breakdown
0%24.3%Other 23.2%

Institutions

Fields

  • Medicine71.7%
  • Biochemistry, Genetics and Molecular Biology21.3%
  • Immunology and Microbiology2.3%
  • Computer Science0.9%
  • Engineering0.6%
  • Chemistry0.5%
  • Other2.7%

Topics

  • Lung Cancer Treatments and Mutations14.1%
  • Lung Cancer Research Studies7.1%
  • Lung Cancer Diagnosis and Treatment6.7%
  • Cancer Immunotherapy and Biomarkers6.2%
  • Cancer Genomics and Diagnostics4%
  • Colorectal Cancer Treatments and Studies1.9%
  • Other60%

Coauthors

All papers

Open in search
  1. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

    Authors: Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn, Marina Chiara Garassino, Hye Ryun Kim, Suresh S. Ramalingam, Frances A. Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S.M.E. Theelen, Chee Khoon Lee, Martin Sebastian, Alison Templeton, Helen Mann, Marcelo Marotti, Serban Ghiorghiu, Vassiliki A. Papadimitrakopoulou - New England Journal of Medicine 2016 cited by 3,329

  2. Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer

    Authors: Yi‐Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lü, Kye Young Lee, Charuwan Akewanlop, Chong‐Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S. Herbst - New England Journal of Medicine 2020 cited by 1,756

  3. Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

    Authors: Masahiro Tsuboi, Roy S. Herbst, Thomas John, Terufumi Kato, Margarita Majem, Christian Grohé, Jie Wang, Jonathan W. Goldman, Shun Lü, Wu‐Chou Su, Filippo de Marinis, Frances A. Shepherd, Ki Hyeong Lee, Nhieu Thi Le, Arunee Dechaphunkul, Dariusz M. Kowalski, Lynne Poole, Ana Bolanos, Yuri Rukazenkov, Yi‐Long Wu - New England Journal of Medicine 2023 cited by 612

  4. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

    Authors: Jean‐Pierre Pignon, Hélène Tribodet, Giorgio V. Scagliotti, Jean-Yves Douillard, Frances A. Shepherd, Richard Stephens, Ariane Dunant, Valter Torri, Rafael Rosell, Lesley Seymour, Stephen Spiro, Estelle Rolland, Roldano Fossati, D. Aubert, Keyue Ding, David Waller, Thierry Le Chevalier - Journal of Clinical Oncology 2008 cited by 2,670

  5. EGFR Mutations and Lung Cancer

    Authors: Gilda da Cunha Santos, Frances A. Shepherd, Ming‐Sound Tsao - Annual Review of Pathology Mechanisms of Disease 2011 cited by 970

  6. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

    Authors: Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth, Ki Hyeong Lee, Alexander Luft, Myung‐Ju Ahn, Michel M. van den Heuvel, Manuel Cobo, David Vicente, Alexey Smolin, Vladimir Moiseyenko, Scott Antonia, Sylvestre Le Moulec, G. Robinet, Ronald B. Natale, Jeffrey Schneider, Frances A. Shepherd, Sarayut Lucien Geater, Edward B. Garon, Edward S. Kim, Sarah B. Goldberg, Kazuhiko Nakagawa, Rajiv Raja, Brandon W. Higgs, Anne-Marie Boothman, Luping Zhao, Urban Scheuring, Paul K. Stockman, Vikram K. Chand, Solange Peters, for the MYSTIC Investigators - JAMA Oncology 2020 cited by 628

  7. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

    Authors: Roy S. Herbst, Yi‐Long Wu, Thomas John, Christian Grohé, Margarita Majem, Jie Wang, Terufumi Kato, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Chong‐Jen Yu, Hữu Vĩnh Vũ, Shun Lü, Kye Young Lee, Guzel Mukhametshina, Charuwan Akewanlop, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Damien Urban, Xiangning Huang, Ana Bolanos, Marta Stachowiak, Masahiro Tsuboi - Journal of Clinical Oncology 2023 cited by 389

  8. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes

    Authors: James McKay, Rayjean J Hung, Younghun Han, Xuchen Zong, Robert Carreras‐Torres, David C. Christiani, Neil E. Caporaso, Mattias Johansson, Xiangjun Xiao, Yafang Li, Jinyoung Byun, Alison M. Dunning, Karen A. Pooley, David C. Qian, Xuemei Ji, Geoffrey Liu, Maria Timofeeva, Stig E. Bojesen, Xifeng Wu, Loı̈c Le Marchand, Demetrius Albanes, Heike Bickeböller, Melinda C. Aldrich, William S. Bush, Adonina Tardón, Gad Rennert, M. Dawn Teare, John K. Field, Lambertus A. Kiemeney, Philip Lazarus, Aage Haugen, Stephen Lam, Matthew B. Schabath, Angeline S. Andrew, Hongbing Shen, Yun‐Chul Hong, Jian‐Min Yuan, Pier Alberto Bertazzi, Angela Cecilia Pesatori, Yuanqing Ye, Nancy Diao, Li Su, Ruyang Zhang, Yonathan Brhane, Natasha B. Leighl, Jakob Sidenius Johansen, Anders Mellemgaard, Walid Saliba, Christopher A. Haiman, Lynne R. Wilkens, Ana Fernández‐Somoano, Guillermo Fernández‐Tardón, Erik H.F.M. van der Heijden, Jin Hee Kim, Juncheng Dai, Zhibin Hu, Michael P.A. Davies, Michael W. Marcus, Hans Brunnström, Jonas Manjer, Olle Melander, David C. Muller, Kim Overvad, Antonia Trichopoulou, ­Rosario ­Tumino, Jennifer A. Doherty, Matt P Barnett, Chu Chen, Gary E. Goodman, Angela Cox, Fiona Taylor, Penella J. Woll, Irene Brüske, H‐Erich Wichmann, Judith Manz, Thomas R Muley, Angela Risch, Albert Rosenberger, Kjell Grankvist, Mikael Johansson, Frances A. Shepherd, Ming‐Sound Tsao, Susanne M. Arnold, Eric B. Haura, Ciprian Bolca, Ivana Holcátová, Vladimí­r Janout, Milica Kontić, Jolanta Lissowska, Anush Mukeria, Simona Ognjanovic, Tadeusz Orłowski, Ghislaine Scélo, Beata Świątkowska, Давид Заридзе, Per Bakke, Vidar Skaug, Shanbeh Zienolddiny, Eric J. Duell, Lesley M. Butler and 40 more - Nature Genetics 2017 cited by 794

  9. EGFR -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

    Authors: Nicolas Marcoux, Scott Gettinger, Grainne M. O’Kane, Kathryn C. Arbour, Joel W. Neal, Hatim Husain, Tracey L. Evans, Julie R. Brahmer, Alona Muzikansky, Philip Bonomi, Salvatore Del Prete, Anna Wurtz, Anna F. Farago, Dora Dias‐Santagata, Mari Mino–Kenudson, Karen L. Reckamp, Helena A. Yu, Heather A. Wakelee, Frances A. Shepherd, Zofia Piotrowska, Lecia V. Sequist - Journal of Clinical Oncology 2018 cited by 471

  10. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

    Authors: Juliann Chmielecki, Tony Mok, Yi‐Long Wu, Ji‐Youn Han, Myung‐Ju Ahn, Suresh S. Ramalingam, Thomas John, Isamu Okamoto, James Chih‐Hsin Yang, Frances A. Shepherd, Krishna C. Bulusu, Gianluca Laus, Barbara Collins, J. Carl Barrett, Ryan J. Hartmaier, Vassiliki A. Papadimitrakopoulou - Nature Communications 2023 cited by 173

  11. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

    Authors: Vassiliki A. Papadimitrakopoulou, Tony Mok, Ji‐Youn Han, Myung‐Ju Ahn, Angelo Delmonte, Suresh S. Ramalingam, Seung‐Whan Kim, Frances A. Shepherd, Janessa Laskin, Yong He, Hiroaki Akamatsu, Willemijn S.M.E. Theelen, Wu‐Chou Su, Thomas John, Martin Sebastian, Helen Mann, Michele Miranda, Gianluca Laus, Yuri Rukazenkov, Yi‐Long Wu - Annals of Oncology 2020 cited by 276

  12. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

    Authors: Matthew D. Hellmann, Naiyer A. Rizvi, Jonathan W. Goldman, Scott Gettinger, Hossein Borghaei, Julie R. Brahmer, Neal Ready, David E. Gerber, Laura Q.M. Chow, Rosalyn A. Juergens, Frances A. Shepherd, Scott A. Laurie, William J. Geese, Shruti Agrawal, Tina C. Young, Xuemei Li, Scott Antonia - The Lancet Oncology 2016 cited by 961

  13. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer

    Authors: Pasi A. Jänne, David Planchard, Kunihiko Kobayashi, Ying Cheng, Chee Khoon Lee, Natalia Valdiviezo, К. К. Лактионов, Tsung‐Ying Yang, Yan Yu, Terufumi Kato, Liyan Jiang, Busyamas Chewaskulyong, Sarayut Lucien Geater, Jean-Marc Maurel, Carlos A. Rojas, Toshiaki Takahashi, Libor Havel, Frances A. Shepherd, Kentaro Tanaka, Dana Ghiorghiu, Neha P. Amin, Elena Armenteros-Monterroso, Xiangning Huang, Ammar Chaudhry, James Chih‐Hsin Yang - Journal of Clinical Oncology 2023 cited by 125

  14. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

    Authors: Kathy S. Albain, Ruth Swann, Valerie W. Rusch, Andrew T. Turrisi, Frances A. Shepherd, Colum J Smith, Yuhchyau Chen, Robert B. Livingston, Richard H. Feins, David R. Gandara, Willard A. Fry, Gail Darling, David H. Johnson, Mark R. Green, Robert C. Miller, Joanne Ley, W. Sause, James D. Cox - The Lancet 2009 cited by 1,474

  15. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

    Authors: Christian Rolfo, Philip C. Mack, Giorgio V. Scagliotti, Paul Baas, Fabrice Barlési, Trever G. Bivona, Roy S. Herbst, Tony Mok, Nir Peled, Robert Pirker, Luis E. Raez, Martin Reck, Jonathan W. Riess, Lecia V. Sequist, Frances A. Shepherd, Lynette M. Sholl, Daniel Shao-Weng Tan, Heather A. Wakelee, Ignacio I. Wistuba, Murry W. Wynes, David P. Carbone, Fred R. Hirsch, David R. Gandara - Journal of Thoracic Oncology 2018 cited by 662

  16. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

    Authors: Benjamin Besse, Elvire Pons‐Tostivint, Keunchil Park, Sylvia Hartl, Patrick M. Forde, Maximilian J. Hochmair, Mark M. Awad, Michael Thomas, Glenwood Goss, Paul Wheatley‐Price, Frances A. Shepherd, Marie Florescu, Parneet Cheema, Quincy S. Chu, Sang‐We Kim, Daniel Morgensztern, Melissa L. Johnson, Sophie Cousin, Dong‐Wan Kim, Mor Moskovitz, David Vicente, Boaz E. Aronson, Rosalind Hobson, Helen J. Ambrose, Sajan Khosla, Avinash Reddy, Deanna L. Russell, Mohamed Reda Keddar, James Conway, J. Carl Barrett, Emma Dean, Rakesh Kumar, Marlene Dressman, Philip J. Jewsbury, Sonia Iyer, Simon T. Barry, Jan Cosaert, John V. Heymach - Nature Medicine 2024 cited by 116

  17. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

    Authors: Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel de Castro, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano Van Kooten, Mircea Dediu, B. Findlay, Dongsheng Tu, D. Johnston, Andrea Bezjak, Gary M. Clark, P. Santabárbara, Lesley Seymour - New England Journal of Medicine 2005 cited by 5,451

  18. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

    Authors: Glenwood Goss, Chun‐Ming Tsai, Frances A. Shepherd, Lyudmila Bazhenova, Jong Seok Lee, Gee‐Chen Chang, Lucio Crinò, Miyako Satouchi, Quincy S. Chu, Toyoaki Hida, Ji‐Youn Han, Óscar Juan, Frank Dunphy, Makoto Nishio, Jin‐Hyoung Kang, Margarita Majem, Helen Mann, Mireille Cantarini, Serban Ghiorghiu, Tetsuya Mitsudomi - The Lancet Oncology 2016 cited by 643

  19. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

    Authors: Charles Butts, Mark A. Socinski, Paul Mitchell, Nick Thatcher, Libor Havel, Maciej Krzakowski, Sergiusz Nawrocki, Tudor–Eliade Ciuleanu, Lionel Bosquée, José Trigo, Alexander I. Spira, Lise Tremblay, Jan Nyman, Rodryg Ramlau, Gun Wickart-Johansson, Peter Ellis, Oleg Gladkov, José Rodrigues Pereira, Wilfried Eberhardt, Christoph Helwig, Andreas Schröder, Frances A. Shepherd - The Lancet Oncology 2013 cited by 526

  20. Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer

    Authors: Élisabeth Brambilla, Gwénaël Le Teuff, Sophie Marguet, Sylvie Lantuéjoul, Ariane Dunant, Stephen L. Graziano, Robert Pirker, Jean-Yves Douillard, Thierry Le Chevalier, Martin Filipits, Rafael Rosell, Robert A. Kratzke, Helmut Popper, Jean‐Charles Soria, Frances A. Shepherd, Lesley Seymour, Ming‐Sound Tsao - Journal of Clinical Oncology 2016 cited by 361

  21. Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

    Authors: Jhanelle E. Gray, Myung‐Ju Ahn, Geoffrey R. Oxnard, Frances A. Shepherd, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng‐Chih Lin, Yi‐Long Wu, Margarita Majem, Oliver Gautschi, Michael Boyer, Krishna C. Bulusu, Aleksandra Markovets, J. Carl Barrett, Rachel Hodge, Astrid McKeown, Ryan J. Hartmaier, Juliann Chmielecki, Vassiliki A. Papadimitrakopoulou, Suresh S. Ramalingam - Clinical Cancer Research 2023 cited by 60

  22. Validation of a Histology-Independent Prognostic Gene Signature for Early-Stage, Non–Small-Cell Lung Cancer Including Stage IA Patients

    Authors: Sandy D. Der, Jenna Sykes, Melania Pintilie, Chang‐Qi Zhu, Dan Strumpf, Geoffrey Liu, Igor Jurišica, Frances A. Shepherd, Ming‐Sound Tsao - Journal of Thoracic Oncology 2013 cited by 404

  23. Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

    Authors: Joachim von Pawel, Robert M. Jotte, David R. Spigel, Mary O’Brien, Mark A. Socinski, J. Mezger, Martin Steins, Leon Bosquée, Jeffrey A. Bubis, Kristiaan Nackaerts, José Trigo, Philip Clingan, Wolfgang Schütte, Paul Lorigan, Martin Reck, Manuel Dómine, Frances A. Shepherd, Shaoyi Li, Markus F. Renschler - Journal of Clinical Oncology 2014 cited by 344

  24. Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model

    Authors: Nadeem Moghal, Quan Li, Erin Stewart, Roya Navab, Masashi Mikubo, Elisa D’Arcangelo, Sebastião N. Martins-Filho, Vibha Raghavan, Nhu‐An Pham, Ming Li, Frances A. Shepherd, Geoffrey Liu, Ming‐Sound Tsao - Journal of Thoracic Oncology 2022 cited by 63